At Intercept, our mission is to build a healthier tomorrow for patients with progressive non-viral liver diseases. Intercept’s lead product, obeticholic acid (OCA), is a first-in-class farnesoid X receptor (FXR) agonist. OCA, marketed under the brand name “Ocaliva®,” is approved in the U.S., EU and Canada for certain patients with primary biliary cholangitis (PBC), a rare autoimmune liver disease. Ocaliva® was the first product to be approved for PBC in over twenty years and our team is proud to have been pioneers in providing the first second-line treatment option to patients with such critical need. The Ocaliva® launch in 2016 also marked Intercept’s successful transition from a development-stage company to a fully integrated commercial organization with continued growth.
In February 2019, Intercept reported positive topline results from the Phase 3 REGENERATE study of OCA in patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH). REGENERATE is the first and largest Phase 3 study in NASH – a chronic disease that threatens the lives of millions of people in the U.S. alone. Currently, there are no available treatments for NASH, and Intercept is among the leading companies focused on the disease.
Based on the positive results from REGENERATE, Intercept submitted the first new drug application for a NASH treatment to the U.S. FDA in September 2019. This is an exciting time for Intercept, as the organization prepares for a potential approval and launch in NASH. As part of this effort, Intercept is beginning to build a new commercial organization, and this opportunity in Sales will play a pivotal role in preparing the company for the successful anticipated launch of OCA’s second indication.
We currently have an opportunity for an experienced Key Account Manager (KAM), with a strong track record, to join our German Commercial team on a field-based basis, covering the Hamburg, Mecklenburg-West Pomerania, and Schleswig-Holstein territory.
The KAM is of pivotal importance as he or she is the company’s representative to pharmacists, physicians and other stakeholders in hospitals and office based locations and selected accounts in the community. The KAM is responsible for customers identified as being relevant to use our drugs for the benefit of patients. He or she will be responsible to develop and drive sales in an assigned district and accounts. A close cooperation with the field based Medical team is fundamental for this exciting job opportunity. The successful candidate should have the ability to build up and develop the infrastructure in the district to support growth and productivity goals. He or she will be highly motivated and capable of working autonomously but also in a team of professionals to help drive the success of our products and the company. The successful candidate should be energetic, confident, independent and entrepreneurial with a track record of proven success in previous jobs facing liver or gastro specialists or in a similar specialist environment.
The detailed accountabilities, the candidate profile and required experience is set out in the following brief.
The Key Account Manager is reporting to the Regional Sales Manager.
REQUIRED KNOWLEDGE AND ABILITIES:
This is a unique opportunity to make a huge impact as individual contributor in the German Commercial a team, and to play key role in the success of the expansion of Intercept Germany.
To apply, please send an up-to-date CV and cover letter in English